These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 20014825

  • 1. Arabinogalactan-folic acid-drug conjugate for targeted delivery and target-activated release of anticancer drugs to folate receptor-overexpressing cells.
    Pinhassi RI, Assaraf YG, Farber S, Stark M, Ickowicz D, Drori S, Domb AJ, Livney YD.
    Biomacromolecules; 2010 Jan 11; 11(1):294-303. PubMed ID: 20014825
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Multifunctional mitoxantrone-conjugated magnetic nanosystem for targeted therapy of folate receptor-overexpressing malignant cells.
    Barar J, Kafil V, Majd MH, Barzegari A, Khani S, Johari-Ahar M, Asgari D, Coukos G, Omidi Y.
    J Nanobiotechnology; 2015 Mar 26; 13():26. PubMed ID: 25880772
    [Abstract] [Full Text] [Related]

  • 4. The folate receptor alpha is frequently overexpressed in osteosarcoma samples and plays a role in the uptake of the physiologic substrate 5-methyltetrahydrofolate.
    Yang R, Kolb EA, Qin J, Chou A, Sowers R, Hoang B, Healey JH, Huvos AG, Meyers PA, Gorlick R.
    Clin Cancer Res; 2007 May 01; 13(9):2557-67. PubMed ID: 17473184
    [Abstract] [Full Text] [Related]

  • 5. Peptide-based pharmacomodulation of a cancer-targeted optical imaging and photodynamic therapy agent.
    Stefflova K, Li H, Chen J, Zheng G.
    Bioconjug Chem; 2007 May 01; 18(2):379-88. PubMed ID: 17298029
    [Abstract] [Full Text] [Related]

  • 6. Augmented anticancer activity of a targeted, intracellularly activatable, theranostic nanomedicine based on fluorescent and radiolabeled, methotrexate-folic Acid-multiwalled carbon nanotube conjugate.
    Das M, Datir SR, Singh RP, Jain S.
    Mol Pharm; 2013 Jul 01; 10(7):2543-57. PubMed ID: 23683251
    [Abstract] [Full Text] [Related]

  • 7. A Carrier-Free Folate Receptor-Targeted Ursolic Acid/Methotrexate Nanodelivery System for Synergetic Anticancer Therapy.
    Lan JS, Qin YH, Liu L, Zeng RF, Yang Y, Wang K, Ding Y, Zhang T, Ho RJY.
    Int J Nanomedicine; 2021 Jul 01; 16():1775-1787. PubMed ID: 33692622
    [Abstract] [Full Text] [Related]

  • 8. Selective delivery of CB300638, a cyclopenta[g]quinazoline-based thymidylate synthase inhibitor into human tumor cell lines overexpressing the alpha-isoform of the folate receptor.
    Theti DS, Bavetsias V, Skelton LA, Titley J, Gibbs D, Jansen G, Jackman AL.
    Cancer Res; 2003 Jul 01; 63(13):3612-8. PubMed ID: 12839949
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Functional aspects of membrane folate receptors in human breast cancer cells with transport-related resistance to methotrexate.
    Pinard MF, Jolivet J, Ratnam M, Kathmann I, Molthoff C, Westerhof R, Schornagel JH, Jansen G.
    Cancer Chemother Pharmacol; 1996 Jul 01; 38(3):281-8. PubMed ID: 8646804
    [Abstract] [Full Text] [Related]

  • 11. Targeted drug delivery via folate receptors.
    Zhao X, Li H, Lee RJ.
    Expert Opin Drug Deliv; 2008 Mar 01; 5(3):309-19. PubMed ID: 18318652
    [Abstract] [Full Text] [Related]

  • 12. Efficient delivery of an antisense oligodeoxyribonucleotide formulated in folate receptor-targeted liposomes.
    Chiu SJ, Marcucci G, Lee RJ.
    Anticancer Res; 2006 Mar 01; 26(2A):1049-56. PubMed ID: 16619505
    [Abstract] [Full Text] [Related]

  • 13. Folic acid modified cationic γ-cyclodextrin-oligoethylenimine star polymer with bioreducible disulfide linker for efficient targeted gene delivery.
    Zhao F, Yin H, Zhang Z, Li J.
    Biomacromolecules; 2013 Feb 11; 14(2):476-84. PubMed ID: 23323627
    [Abstract] [Full Text] [Related]

  • 14. Severe folate restriction results in depletion of and alteration in the composition of the intracellular folate pool, moderate sensitization to methotrexate and trimetrexate, upregulation of endogenous DHFR activity, and overexpression of metallothionein II and folate receptor alpha that, upon folate repletion, confer drug resistance to CHL cells.
    Zhu WY, Bunni M, Priest DG, DiCapua JL, Dressler JM, Chen Z, Melera PW.
    J Exp Ther Oncol; 2002 Feb 11; 2(5):264-77. PubMed ID: 12416030
    [Abstract] [Full Text] [Related]

  • 15. Folic acid conjugated guar gum nanoparticles for targeting methotrexate to colon cancer.
    Sharma M, Malik R, Verma A, Dwivedi P, Banoth GS, Pandey N, Sarkar J, Mishra PR, Dwivedi AK.
    J Biomed Nanotechnol; 2013 Jan 11; 9(1):96-106. PubMed ID: 23627072
    [Abstract] [Full Text] [Related]

  • 16. [Folate receptor-mediated antitumor drugs].
    Zhao J, Cao SL, Zheng XL, Zhao B.
    Yao Xue Xue Bao; 2009 Feb 11; 44(2):109-14. PubMed ID: 19408677
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Folate targeting enables durable and specific antitumor responses from a therapeutically null tubulysin B analogue.
    Leamon CP, Reddy JA, Vetzel M, Dorton R, Westrick E, Parker N, Wang Y, Vlahov I.
    Cancer Res; 2008 Dec 01; 68(23):9839-44. PubMed ID: 19047164
    [Abstract] [Full Text] [Related]

  • 20. Folate receptor-mediated drug targeting: from therapeutics to diagnostics.
    Hilgenbrink AR, Low PS.
    J Pharm Sci; 2005 Oct 01; 94(10):2135-46. PubMed ID: 16136558
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.